While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's ... events such as heart attacks, strokes, and mortality in persons with diabetes and known heart disease.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease.

Novo Nordisk’s Ozempic (semaglutide ... approval in 2020 to reduce the risk of major cardiovascular events in adults with T2D and known heart disease. The FDA’s latest decision on the drug was ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease ... heart failure; acute kidney failure; malignant tumor; and serious ...

GLP-1 drugs are being studied in a growing number of indications, and Novo Nordisk ... events — heart attack, stroke, or death — in adults with type 2 diabetes and known heart disease.

As per its FDA label, Ozempic is also indicated to reduce the risk of major adverse cardiovascular events in adults with T2D and established heart disease. Novo Nordisk is eyeing up further ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Novo Nordisk (NVO ... risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease. Semaglutide's main competitor in the ...

(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type ...